Ovarian Cancer Drugs Market by Key
Segments | Forecast Years:
2024-
2030
| CAGR:8.3%
{reportSlug=global-ovarian-cancer-drugs-market, reportId=20244, mktKeyword=Ovarian Cancer Drugs, cagr=8.30, publishDate=Apr 2024, priceOption2=7500, reportTitle=Ovarian Cancer Drugs Comprehensive Study by Type (PARP inhibitors, PD-L1 inhibitors, Angiogenesis Inhibitors, Others), Application (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Others), Treatment Categories (Chemotherapy, Radiation therapy, Immunotherapy, Autologous stem-cell transplantation, Targeted Therapy), Disease Type (Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Ovarian Stromal Tumors, Primary Peritoneal Carcinoma), Chemotherapy Drugs (Carboplatin, Cisplatin, Docetaxel, Paclitaxel, Other Medication (Cyclophosphamide, Doxorubicin, Gemcitabine, Oxaliplatin, and Topotecan).), Physical Examination (Biopsy, Blood tests, Human Chorionic Gonadotropin (hCG) test, Ultrasound, MRI (Magnetic resonance imaging), PET (Positron emission tomography), CT scans, Biopsy, Blood tests, Human Chorionic Gonadotropin (hCG) test, Ultrasound, MRI (Magnetic resonance imaging), PET (Positron emission tomography), CT scans), Pricing analysis (IPP, OPP, RAP), Distribution channel (Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy) Players and Region - Global Market Outlook to 2030, baseYr=2023, totalTableFig=220, priceOption1=3750, forecastYr=2030, noOfPages=211, reportKey=20174, breadcrum=Global Ovarian Cancer Drugs Market}
We do not share your information with anyone. However, we may send you
emails based on your report interest from time to time. You may contact
us at any time to opt-out.
Select User Access Type
Key Highlights of Report
Apr 2024
211 Pages
86 Tables
Base Year: 2023Coverage: 15+ Companies; 18
Countries